Imatinib resistance in gastrointestinal stromal tumors

被引：36

作者：

Chen L.L. ^{[1
]}

Sabripour M. ^{[1
]}

Andtbacka R.H.I. ^{[1
]}

Patel S.R. ^{[1
]}

Feig B.W. ^{[1
]}

Macapinlac H.A. ^{[1
]}

Choi H. ^{[1
]}

Wu E.F. ^{[1
]}

Frazier M.L. ^{[1
]}

Benjamin R.S. ^{[1
]}

机构：

[1] Department of Sarcoma, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

来源：

Current Oncology Reports | 2005年 / 7卷 / 4期

关键词：

Imatinib; Gastrointestinal Stromal Tumor; Imatinib Therapy; STI571; Imatinib Treatment;

D O I：

10.1007/s11912-005-0053-6

中图分类号：

学科分类号：

摘要：

Conventional chemotherapeutic drugs are ineffective in treatment of gastrointestinal stromal tumors (GISTs). Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs. Unfortunately, imatinib resistance has emerged. The reported mechanism of imatinib resistance in GISTs involves missense mutation in the kinase domain of KIT, including Thr670IIe, Tyr823Asp, and Val654Ala. The established mechanisms and potential mechanisms of imatinib resistance in GISTs, the imaging studies indicative of early development of imatinib resistance, and the management of imatinib-resistant GISTs are discussed. Copyright © 2005 by Current Science Inc.

引用

页码：293 / 299

页数：6

共 32 条

[1]

Hirota S., Isozaki K., Moriyama Y., Et al., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, pp. 577-580, (1998)

[2]

Koh J.S., Trent J., Chen L., Et al., Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate, Histol. Histopathol., 19, pp. 565-574, (2004)

[3]

Antonescu C.R., Sommer G., Sarran L., Et al., Association of KIT exon 9 mutation with nongastric primary site and aggressive behavior: IUT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors, Clin. Cancer Res., 9, pp. 3329-3337, (2003)

[4]

Taniguchi M., Nishida T., Hirota S., Et al., Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors, Cancer Res., 59, pp. 4297-4300, (1999)

[5]

Sandberg A.A., Bridge J.A., Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Gastrointestinal stromal tumors, Cancer Genet. Cytogenet., 135, pp. 1-22, (2002)

[6]

Heinrich M.C., Corless C.L., Demetri G.D., Et al., Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J. Clin. Oncol., 21, pp. 4342-4349, (2003)

[7]

Heinrich M.C., Corless C.L., Deunsing A., Et al., PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 299, pp. 708-710, (2003)

[8]

Hirota S., Ohashi A., Nishida T., Et al., Gain-of-function mutations of platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors, Gastroenterology, 125, pp. 660-667, (2003)

[9]

Manley P.W., Cowan-Jacob S.W., Buchdunger E., Et al., Imatinib: A selective tyrosine kinase inhibitor, Eur. J. Cancer, 38, (2002)

[10]

van Oosterom A.T., Judson I., Verweij J., Et al., Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study, Lancet, 358, pp. 1421-1423, (2001)

← 1 2 3 4 →